- Previous Close
2.2100 - Open
2.2288 - Bid 1.6000 x 200
- Ask 2.7100 x 200
- Day's Range
2.0800 - 2.2288 - 52 Week Range
1.9600 - 3.0900 - Volume
73,788 - Avg. Volume
255,286 - Market Cap (intraday)
85.462M - Beta (5Y Monthly) 1.61
- PE Ratio (TTM)
-- - EPS (TTM)
-0.4800 - Earnings Date May 7, 2025 - May 12, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
3.25
Oramed Pharmaceuticals Inc. engages in the research and development of pharmaceutical solutions for the treatment of diabetes and for the use of orally ingestible capsules for delivery of polypeptides. The company's product portfolio includes ORMD-0801, an oral insulin capsule, which is in phase III clinical trial for the treatment of individuals with diabetes, as well as in phase II clinical trial for the treatment of non-alcoholic steatohepatitis; and ORA-D-013-1 and ORA-D-013-2, which have completed phase II clinical trial for the treatment of type 2 diabetes. It has license agreements with Oravax Medical Inc. to commercialize oral vaccines for COVID-19 and other novel coronaviruses. Oramed Pharmaceuticals Inc. was incorporated in 2002 and is headquartered in New York.
www.oramed.comRecent News: ORMP
View MorePerformance Overview: ORMP
Trailing total returns as of 3/31/2025, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: ORMP
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: ORMP
View MoreValuation Measures
Market Cap
89.09M
Enterprise Value
-52.47M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
0.61
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-4.12%
Return on Equity (ttm)
2.89%
Revenue (ttm)
--
Net Income Avi to Common (ttm)
4.46M
Diluted EPS (ttm)
-0.4800
Balance Sheet and Cash Flow
Total Cash (mrq)
142.3M
Total Debt/Equity (mrq)
0.28%
Levered Free Cash Flow (ttm)
-2.41M